Targeting Epigenetic Regulators in Cancer: The Promise of BET and HDAC Inhibitors - Promega Connections
This blog was written in collaboration with Tian Yang, Associate Product Manager at Promega. Cancer is often driven not only by genetic mutations, but by changes in how genes are turned on or off—epigenetic alterations. Two key players in this space are bromodomain and extra-terminal (BET) proteins and histone deacetylases (HDACs). BET proteins help activate […]| Promega Connections
